Passa al contenuto
Merck

Cold-inducible RNA-binding protein mediates neuroinflammation in cerebral ischemia.

Biochimica et biophysica acta (2014-03-13)
Mian Zhou, Weng-Lang Yang, Youxin Ji, Xiaoling Qiang, Ping Wang
ABSTRACT

Neuroinflammation is a key cascade after cerebral ischemia. Excessive production of proinflammatory mediators in ischemia exacerbates brain injury. Cold-inducible RNA-binding protein (CIRP) is a newly discovered proinflammatory mediator that can be released into the circulation during hemorrhage or septic shock. Here, we examine the involvement of CIRP in brain injury during ischemic stroke. Stroke was induced by middle cerebral artery occlusion (MCAO). In vitro hypoxia was conducted in a hypoxia chamber containing 1% oxygen. CIRP and tumor necrosis factor-α (TNF-α) levels were assessed by RT-PCR and Western blot analysis. CIRP is elevated along with an upregulation of TNF-α expression in mouse brain after MCAO. In CIRP-deficient mice, the brain infarct volume, induction of TNF-α, and activation of microglia are markedly reduced after MCAO. Using microglial BV2 cells, we demonstrate that hypoxia induces the expression, translocation, and release of CIRP, which is associated with an increase of TNF-α levels. Addition of recombinant murine (rm) CIRP directly induces TNF-α release from BV2 cells and such induction is inhibited by neutralizing antisera to CIRP. Moreover, rmCIRP activates the NF-κB signaling pathway in BV2 cells. The conditioned medium from BV2 cells exposed to hypoxia triggers the apoptotic cascade by increasing caspase activity and decreasing Bcl-2 expression in neural SH-SY5Y cells, which is inhibited by antisera to CIRP. Extracellular CIRP is a detrimental factor in stimulating inflammation to cause neuronal damage in cerebral ischemia. Development of an anti-CIRP therapy may benefit patients with brain ischemia.

MATERIALI
N° Catalogo
Marchio
Descrizione del prodotto

Sigma-Aldrich
Acido citrico, meets analytical specification of Ph. Eur., BP, USP, E330, anhydrous, 99.5-100.5% (based on anhydrous substance)
Sigma-Aldrich
BIS-TRIS, ≥98.0% (titration)
Sigma-Aldrich
Trichloroacetic acid solution, 6.1 N
Sigma-Aldrich
Acido citrico, ≥99.5%, FCC, FG
Sigma-Aldrich
Acido citrico, anhydrous, suitable for cell culture, suitable for plant cell culture
USP
Acido citrico, United States Pharmacopeia (USP) Reference Standard
Sigma-Aldrich
BIS-TRIS, BioUltra, ≥99.0% (NT)
Sigma-Aldrich
Acido tricloroacetico, BioUltra, ≥99.5% (T)
Sigma-Aldrich
BIS-TRIS, BioPerformance Certified, suitable for cell culture, suitable for insect cell culture, ≥98.0%
Sigma-Aldrich
Acido citrico, BioUltra, anhydrous, ≥99.5% (T)
Sigma-Aldrich
Acido tricloroacetico, suitable for electrophoresis, suitable for fixing solution (for IEF and PAGE gels), ≥99%
Sigma-Aldrich
Acido citrico, ACS reagent, ≥99.5%
Sigma-Aldrich
BIS-TRIS, BioXtra, ≥98.0% (titration)
Sigma-Aldrich
Acido tricloroacetico, ACS reagent, ≥99.0%
SAFC
BIS-TRIS
Sigma-Aldrich
Acido citrico, 99%
Sigma-Aldrich
2-Hydroxybutyric acid sodium salt, 97%
Supelco
Acido citrico, Pharmaceutical Secondary Standard; Certified Reference Material
SAFC
BIS-TRIS
Sigma-Aldrich
Acido tricloroacetico, ≥99.0% (titration)
Sigma-Aldrich
Acido citrico, anhydrous, free-flowing, Redi-Dri, ACS reagent, ≥99.5%
Sigma-Aldrich
Acido tricloroacetico, BioXtra, ≥99.0%
Supelco
Acido citrico, certified reference material, TraceCERT®, Manufactured by: Sigma-Aldrich Production GmbH, Switzerland
Sigma-Aldrich
Acido tricloroacetico, ACS reagent, for the determination of Fe in blood according to Heilmeyer, ≥99.5%
Acido citrico, anhydrous, European Pharmacopoeia (EP) Reference Standard